Health
China Sinopharm’s potential COVID-19 vaccine triggers antibodies in clinical trials – CNA
BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
BEIJING: A coronavirus vaccine candidate developed by a unit of China National Pharmaceutical Group (Sinopharm) appeared to be safe and triggered antibody-based immune responses in early and mid-stage trials, researchers said.
The potential vaccine has already moved into a late-stage trial, one of a handful of candidates being tested on several thousand people to see if they are effective enough to win regulatory approval.
Advertisement
Advertisement
Sinopharm is testing the potential vaccin…
-
General8 hours agoCampers evacuated, residents on alert as Moreton Island bushfire intensifies
-
Noosa News15 hours agoPerth Royal Show vendors upset by price hikes, say crowds are down in 2025
-
Business16 hours agoBell Potter names the best ASX shares to buy in October
-
General15 hours agoTasmanian woman drowns on day 5 of multi-day Franklin River rafting trip